로딩 중…
지수 로딩 중…
유바이오로직스
206650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩9,270-2.83%
2026-06-19
Price Chart
유바이오로직스-26.60%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 340.43B KRW |
| Revenue | 125.33B KRW |
| Net Income | 29.23B KRW |
| Total Assets | 235.16B KRW |
| Net Assets | 179.72B KRW |
| Employees | 353 |
| Value | |
| P/E | 11.65x |
| P/B | 1.89x |
| P/S | 2.72x |
| FCF Yield | 10.52% |
| Profitability | |
| ROE | 16.27% |
| ROA | 12.43% |
| Op. Margin | 36.66% |
| Revenue Growth | -60.41% |
| Earnings Growth | -76.66% |
| Financial Health | |
| Debt Ratio | 130.85% |
| Total Debt | 0 KRW |
| FCF | 35.80B KRW |
| Cash | 21.31B KRW |
| Current Ratio | 3.99x |
| Performance | |
| 1Y Return | -26.60% |
| 1M Return | -12.88% |
| From 52W High | -47.63% |
| 1Y MDD | -44.51% |
| Trading | |
| Volume | 282,432 shares |
| Foreign Own. | 6.06% |
| Per Share | |
| EPS | 798 KRW |
| BPS | 4,894 KRW |
Company Info
Established in 2010 and listed on KOSDAQ in 2017, this company is a specialized venture in vaccine manufacturing and biopharmaceutical contract research and manufacturing. It operates vaccine businesses, supplying 'Euvichol-S' to UNICEF and others, and provides biopharmaceutical CRMO services, with first and second factories and a research institute in Chuncheon. By expanding its cholera vaccine facilities, the company has established an annual production system of up to 90 million doses. It aims to become a global vaccine company through the development of diverse vaccine pipelines. Eubiologics is headquartered in Gangnam-gu, Seoul Special City.